Tang Kevin C's Form 4 filing
Aurinia Pharmaceuticals Inc. (AUPH) · filed Mar 4, 2025
- Accession no.
- 0001415889-25-006589
- Filed
- Mar 4, 2025
- Trade date
- Feb 28-Mar 4, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 6 non-derivative transactions and 0 derivative transactions. Open-market purchases total $12.7M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Tang Kevin CCIK 0001178579 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 28, 2025 | Common Shares | PPurchaseAcquired | +399,280 | $7.85 | +$3,134,348 | 8,828,780 | Indirect | |
| Mar 3, 2025 | Common Shares | PPurchaseAcquired | +100,720 | $7.97 | +$802,738.4 | 8,929,500 | Indirect | |
| Mar 3, 2025 | Common Shares | PPurchaseAcquired | +351,962 | $8.02 | +$2,822,735.24 | 9,281,462 | Indirect | |
| Mar 4, 2025 | Common Shares | PPurchaseAcquired | +148,038 | $8.00 | +$1,184,304 | 9,429,500 | Indirect | |
| Mar 4, 2025 | Common Shares | PPurchaseAcquired | +500,000 | $7.92 | +$3,960,000 | 9,929,500 | Indirect | |
| Mar 4, 2025 | Common Shares | PPurchaseAcquired | +100,000 | $8.09 | +$809,000 | 10,029,500 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.